Important Announcement


ChemIDplus is moving to PubChem in December 2022.
Please see the NLM Technical Bulletin article for more information.

Skip Navigation
ChemIDplus LiteBrowseAdvanced

Substance Name: Tovetumab [USAN:INN]
RN: 1243266-04-7


  • A receptor platelet-derived growth factor alpha (PDGFRalpha) monoclonal antibody for treatment of advanced solid tumors.
  • NCI: A humanized monoclonal antibody directed against the platelet-derived growth factor receptor (PDGFR) alpha with potential antineoplastic activity. Anti-PDGFR alpha monoclonal antibody MEDI-575 inhibits activation of the cell-surface tyrosine kinase PDGFR alpha subunit and subsequent triggering of mitogenic signaling pathways, including the JAK/STAT, PI3K/Akt, and MAP kinase pathways. PDGFR alpha acts as a mitogenic signaling receptor for cells of mesenchymal origin and inhibition of receptor activity may inhibit tumor cell proliferation. (NCI Thesaurus)

Molecular Formula

  • C6400-H9906-N1726-O2002-S54

Classification Code

  • Treatment of Cancer
* denotes mobile formatted website

Links to Resources

NLM Resources (File Locators)

Other Resources (Internet Locators)

Names and Synonyms

Name of Substance

  • Tovetumab [USAN:INN]


  • anti-PDGFR alpha monoclonal antibody MEDI-575
  • Immunoglobulin G2, anti-(human platelet-derived growth factor receptor alpha) (human monoclonal MEDI-575 heavy chain), disulfide with human monoclonal MEDI-575 kappa-chain, dimer
  • MEDI 575
  • MEDI-575
  • Tovetumab
  • UNII-2XY62K75UV

Registry Numbers

CAS Registry Number

  • 1243266-04-7


  • 2XY62K75UV

System Generated Number

  • 1243266047